News
XCUR
1.140
-7.69%
-0.095
Weekly Report: what happened at XCUR last week (0921-0925)?
Weekly Report · 1d ago
Weekly Report: what happened at XCUR last week (0914-0918)?
Weekly Report · 09/21 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/17 21:06
Exicure Receives Nasdaq Extension Amid Ongoing Listing Risk
TipRanks · 09/16 15:34
Exicure gets Nasdaq compliance extension
Seeking Alpha · 09/16 12:49
Exicure Receives Nasdaq Extension Through December 2 To Regain Compliance
Benzinga · 09/16 12:01
Weekly Report: what happened at XCUR last week (0907-0911)?
Weekly Report · 09/14 09:00
Weekly Report: what happened at XCUR last week (0831-0904)?
Weekly Report · 09/07 09:00
Weekly Report: what happened at XCUR last week (0824-0828)?
Weekly Report · 08/31 09:00
Weekly Report: what happened at XCUR last week (0817-0821)?
Weekly Report · 08/24 09:00
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 08/21 17:06
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/17 21:06
Weekly Report: what happened at XCUR last week (0810-0814)?
Weekly Report · 08/17 09:00
Weekly Report: what happened at XCUR last week (0803-0807)?
Weekly Report · 08/10 09:00
Exicure Plans To Issue 172,058 Common Shares To GPCR Therapeutics During This Month To Settle $1M Clinical Milestone Payment Obligation
Benzinga · 08/03 13:28
Weekly Report: what happened at XCUR last week (0727-0731)?
Weekly Report · 08/03 09:00
Weekly Report: what happened at XCUR last week (0720-0724)?
Weekly Report · 07/27 09:00
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/20 17:05
Weekly Report: what happened at XCUR last week (0713-0717)?
Weekly Report · 07/20 09:00
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 07/16 12:05
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.